MicroRNA-101 regulates T-cell acute lymphoblastic leukemia progression and chemotherapeutic sensitivity by targeting...

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Acute lymphoblastic leukemia (ALL) remains a significant challenge in hematologic oncology.
• T-cell acute lymphoblastic leukemia (T-ALL) exhibits complex progression mechanisms and chemoresistance.
• MicroRNAs (miRNAs) play crucial roles in regulating gene expression and cellular processes in cancer.

Purpose of the Study:

• To investigate the role of microRNA (miR)-101 in the progression and chemoresistance of T-cell acute lymphoblastic leukemia (T-ALL).
• To identify novel target genes of miR-101 involved in T-ALL pathogenesis.
• To explore the therapeutic potential of miR-101 in T-ALL intervention.

Main Methods:

• Reverse transcription quantitative polymerase chain reaction (RTqPCR) to quantify miR-101 levels in patient samples.
• In vitro assays (CCK-8, flow cytometry, cell invasion assays) to assess miR-101's effects on Jurkat cells.
• Luciferase reporter assays and Western blotting to identify and validate Notch1 as a direct target of miR-101.

Main Results:

• miR-101 was significantly downregulated in T-ALL patient blood samples compared to healthy controls.
• Overexpression of miR-101 in Jurkat cells repressed proliferation and invasion while inducing apoptosis.
• miR-101 directly targets Notch1, suppressing its protein expression and mediating miR-101's tumor-suppressive effects.
• miR-101 enhanced the sensitivity of T-ALL cells to adriamycin chemotherapy.

Conclusions:

• miR-101 functions as a tumor suppressor in T-cell acute lymphoblastic leukemia.
• miR-101 enhances the sensitivity of T-ALL cells to chemotherapeutic agents.
• Notch1 is identified as a novel direct target of miR-101 in T-ALL.
• miR-101 represents a promising therapeutic target for T-cell acute lymphoblastic leukemia.